Eli Lilly shares rise 1.14% premarket after signing a $1.3 billion deal with Superluminal to develop obesity medicines.

Eli Lilly And Company rose 1.14% in premarket trading, driven by the company's recent strategic moves in the obesity treatment market. Eli Lilly has signed a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through AI, targeting obesity and other cardiometabolic diseases. This collaboration leverages Superluminal's AI-driven platform to rapidly discover potential drug candidates, strengthening Lilly's position in the growing obesity treatment market. Additionally, Eli Lilly's announcement of negotiating to raise prices in Europe for its weight-loss drug Mounjaro, aiming to comply with the Trump administration's goal of lowering U.S. prices, has also contributed to the positive sentiment around the stock.